Condition: Myasthenia Gravis, Generalized · Sponsor: Vertex Pharmaceuticals Incorporated
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
This description comes directly from the study's public registry record.
Medical Information · 617-341-6777 · medicalinfo@vrtx.com
Always discuss trial participation with your own doctor first.
| Neurology Offices | Boca Raton, Florida, United States | Recruiting |
| SFM Clinical Reseach, LLC | Boca Raton, Florida, United States | Recruiting |
| Homestead Associates in Research | Homestead, Florida, United States | Recruiting |
| UF Health Jacksonville Respiratory Therapy (PFT and DLCO) | Jacksonville, Florida, United States | Recruiting |
| Y & L Advance Health Care, Inc D/B/A Elite Clinical Research - Neurology | Miami, Florida, United States | Recruiting |
| Quantix Research | Miami, Florida, United States | Recruiting |
| Hawaii Pacific Neuroscience | Honolulu, Hawaii, United States | Recruiting |
| HSHS Medical Group - St. Elizabeth's Hospital | O'Fallon, Illinois, United States | Recruiting |
| Las Vegas Neurology Center | Las Vegas, Nevada, United States | Recruiting |
| Clinical Trials of South Carolina - Neurology | Charleston, South Carolina, United States | Recruiting |
| Ut Erlanger Neurology | Chattanooga, Tennessee, United States | Recruiting |
| Nerve and Muscle Center of Texas - Neurology | Houston, Texas, United States | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07501702